Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Accounts Payables (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Accounts Payables for 3 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables fell 29.52% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, down 29.52% year-over-year, with the annual reading at $1.6 million for FY2025, 29.52% down from the prior year.
  • Accounts Payables hit $1.6 million in Q4 2025 for Compass Therapeutics, down from $3.1 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $4.1 million in Q4 2023 to a low of $724000.0 in Q2 2023.
  • Historically, Accounts Payables has averaged $1.9 million across 3 years, with a median of $1.6 million in 2025.
  • Biggest five-year swings in Accounts Payables: tumbled 58.37% in 2024 and later surged 222.4% in 2025.
  • Year by year, Accounts Payables stood at $4.1 million in 2023, then plummeted by 45.01% to $2.2 million in 2024, then decreased by 29.52% to $1.6 million in 2025.
  • Business Quant data shows Accounts Payables for CMPX at $1.6 million in Q4 2025, $3.1 million in Q3 2025, and $2.6 million in Q2 2025.